Welcome to our dedicated page for Merus SEC filings (Ticker: MRUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Multispecific antibodies may revolutionize cancer therapy, but the disclosures behind Merus N.V.’s Biclonics® platform are anything but simple. From detailed phase 1/2 trial updates to collaboration milestone accounting, Merus filings can overwhelm even seasoned biotech analysts.
Stock Titan’s AI-powered analysis turns that complexity into clarity. Need the Merus quarterly earnings report 10-Q filing? We surface R&D burn rates and cash runway in seconds. Hunting for Merus insider trading Form 4 transactions or monitoring Merus executive stock transactions Form 4? Real-time alerts appear moments after EDGAR posts—no manual refresh required. Our platform also delivers plain-English digests so you’re understanding Merus SEC documents with AI rather than wading through legal jargon.
Every submission, from an 8-K announcing fresh clinical data to the comprehensive 10-K, is mapped to the questions investors actually ask:
- Merus annual report 10-K simplified – find pipeline timelines, collaboration revenue splits, and risk factors in one click.
- Merus 8-K material events explained – track trial readouts, FDA designations, or new licensing deals instantly.
- Merus proxy statement executive compensation – compare leadership incentives to R&D milestones.
Whether you’re performing a quick Merus earnings report filing analysis or need Merus Form 4 insider transactions real-time, Stock Titan provides comprehensive coverage and AI-generated summaries that answer, "Are insiders buying ahead of data?" or "How long will cash last at current burn?" Investors save hours, gain confidence, and never miss a disclosure that could move the stock.
Peter B. Silverman, COO & General Counsel of Merus N.V. (MRUS), executed a planned transaction under Rule 10b5-1 on June 20, 2025. The transaction involved:
- Exercise of 34,000 stock options at $18.61 per share
- Immediate sale of all 34,000 shares at a weighted average price of $52.76 (range: $52.44-$53.06)
- Retained 23,500 unexercised options from original February 14, 2020 grant
This transaction was conducted according to a pre-established Rule 10b5-1 trading plan adopted on March 20, 2025. The exercised options were fully vested, with an original expiration date of February 14, 2030. The sale represents a significant realization of gains, with approximately $1.16 million in gross proceeds before accounting for the exercise cost of $632,740.
Merus N.V. (MRUS) – Form 144 filing overview
The notice covers a proposed sale of 34,000 common shares that were acquired through a non-qualified stock option exercise on 20 Jun 2025. The seller’s identity is not disclosed in the filing, but the transaction will be executed through RBC Capital Markets LLC on NASDAQ.
Based on the Form 144 data, the aggregate market value of the shares being sold is US $1.79 million. With 69.2 million shares outstanding, the proposed sale represents approximately 0.05 % of the company’s shares, indicating a relatively small, routine disposition. No other sales by the same person were reported in the past three months, and no additional remarks or 10b5-1 plan dates were supplied.
The filing is strictly a notice and does not, by itself, confirm that the sale has occurred. It also states that the seller affirms no undisclosed material adverse information regarding Merus exists at the time of filing.
FAQ
What is the current stock price of Merus (MRUS)?
What is the market cap of Merus (MRUS)?
What is Merus N.V. focused on?
How does Merus generate revenue?
What makes Merus's technology unique?
What are the key areas of Merus's clinical pipeline?
Which partnerships support Merus's development efforts?
How does Merus address challenges in the competitive oncology market?
